PRQR - ProQR Therapeutics N.V.

QQQ $ 608.45 $ 0.46 (0.08 %)

DIA $ 471.65 $ -2.94 (-0.62 %)

SPY $ 671.62 $ -0.11 (-0.02 %)

TLT $ 88.93 $ -0.51 (-0.57 %)

GLD $ 375.82 $ -6.91 (-1.8 %)

Previous Close

$ 2.17

Open

$ 2.12

Bid

$ 2.18 x 23

Ask

$ 2.19 x 906

Day's Range

$ 2.10 - $ 2.25

52 Week Range

$ 1.07 - $ 4.00

Volume

302,035

Average Volume

Market Cap

228.31M

Beta (5Y Monthly)

$ 1.07

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ProQR Therapeutics Q3 EPS $(0.10), Inline,...
11/06/2025 12:16:32

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This ...

Chardan Capital Maintains Buy on ProQR The...
11/04/2025 13:26:26

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.

ProQR Therapeutics Gets European Medicines...
10/20/2025 12:12:28

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base...

ProQR Announces Central Committee On Resea...
10/20/2025 12:07:18

12 Health Care Stocks Moving In Tuesday's ...
09/16/2025 21:06:11

Chardan Capital Maintains Buy on ProQR The...
08/08/2025 12:16:40

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.

ProQR Therapeutics Q2 EPS $(0.12) Misses $...
08/07/2025 12:21:46

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of ...

ProQR Therapeutics Q2 EPS $(0.12) Misses $...
08/07/2025 11:25:15

ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of ...

Cantor Fitzgerald Reiterates Overweight on...
06/27/2025 12:40:08

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 pri...

JMP Securities Reiterates Market Outperfor...
06/27/2025 12:31:45

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains ...

ProQR Submits Clinical Trial Application T...
06/26/2025 20:32:07

Oppenheimer Maintains Outperform on ProQR ...
05/13/2025 17:48:47

Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price targ...

ProQR Therapeutics Q1 EPS $(0.10) Misses $...
05/08/2025 11:28:46

Evercore ISI Group Initiates Coverage On P...
04/29/2025 12:39:44

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Outperform rati...

ProQR Names Dennis Hom As CFO
04/14/2025 11:08:39

ProQR Therapeutics Appoints Dennis Hom As CFO
04/14/2025 11:02:23

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a ...

Chardan Capital Maintains Buy on ProQR The...
03/14/2025 12:29:13

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.

HC Wainwright & Co. Maintains Buy on ProQR...
03/14/2025 12:19:58

HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price targe...

ProQR FY24 EPS EUR(0.32) Up From EUR(0.35)...
03/13/2025 11:19:00

The company said € 149.4 million cash and cash equivalents as of end of 2024, providing runway into mid-2027, plus additional p...

this-ralph-lauren-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday

This Ralph Lauren Analyst Begins Coverage ...
02/12/2025 13:53:27